Joint Corp (JYNT) — Titan Protect Analysis

JYNT

Joint Corp

Healthcare · ·

$8.29

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$121M

Total market value of the company

Trailing P/E

94.44

Expensive — high growth expected

Forward P/E

19.62

Based on estimated future earnings — lower means cheaper

Rev Growth

+13.3%

Year-over-year revenue change

Profit Margin

5.7%

How much profit the company keeps from each dollar of revenue

ROE

7.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$9.00

+9% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 3 analysts covering this stock

About Joint Corp

The Joint Corp. operates and is a franchisor and operator of chiropractic clinics in the United States. The company provides services under the franchise agreement, including training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. It operates through a network of franchised clinics, offering routine and affordable chiropractic adjustments using a private pay, non-insurance, cash-based model. The company was incorporated in 2010 and is hea

https://www.thejoint.com

Country: United States Employees: 202 Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.558

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0681

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.540

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-27.4%

Historical annualised return based on price data

Max Drawdown

-50.6%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.11

Moves slightly more than the broader market

52W High

$13.47

38% below the year high

52W Low

$7.50

11% above the year low

Avg Volume

69,944

Average daily shares traded — higher means easier to buy and sell

Short Ratio

13.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.09

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

13.18

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

80.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

6.1%

Profit from core operations before interest and tax

Free Cash Flow

$9M

Positive — the business generates more cash than it spends

Revenue (TTM)

$57M

Total revenue over the last 12 months

Net Income

$1M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$12.00

Target Median

$9.00

Target Low

$9.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go